HK Stock Market Move | SKB BIO(06990) rose more than 10% in early trading; Merck and Kolon Biotec's ADC combination therapy beats K drug single therapy.

date
09:32 22/05/2026
avatar
GMT Eight
Corentec (06990) rose more than 10% in early trading, up 7.14% as of the time of writing, at 486 Hong Kong dollars, with a turnover of 1.1 billion Hong Kong dollars.
SKB BIO (06990) soared more than 10% in the early trading session, and as of the time of writing, it rose by 7.14% to 486 Hong Kong dollars, with a trading volume of 1.1 billion Hong Kong dollars. On the news front, the mid-term analysis results of the OptiTROP-Lung05 study, a collaboration between MSD and Chia Tai Tianqing Pharmaceutical Group, on the TROP2-targeted antibody-drug conjugate (ADC) sacituzumab govitecan (sac-TMT) in combination with Keytruda in first-line treatment of PD-L1 positive non-small cell lung cancer (NSCLC) have made a stunning appearance. This is the world's first ADC-immunotherapy combination scheme to beat Keytruda monotherapy in first-line NSCLC treatment, promising to completely reshape the treatment landscape in this field. It is reported that sac-TMT is the first domestically produced TROP2 ADC in China to be fully approved for marketing with global intellectual property rights. Currently, Chia Tai Tianqing has submitted an application for marketing approval for sac-TMT in the first-line NSCLC indication to the National Medical Products Administration (NMPA) of China and has been accepted and included in the priority review and approval process, potentially expediting its approval for marketing and benefiting Chinese patients.